Verici Dx plc float on AIM
Verici Dx develops tests to understand how a patient will and is responding to organ transplants. One of the most significant threats to a successful transplant, or graft, is the body’s own immune system. Patients’ immune systems differ in how they respond to the presence of the transplanted organ, characterizing this response is called immune phenotyping. Our products and solutions are underpinned by extensive scientific research into the recipient’s immune phenotype and how that impacts on acute rejection, chronic injury and ultimately failure of the transplant. These immuno-profile signatures also inform clinicians as to the optimal strategy for immunosuppression and other therapies for the most successful treatment to ensure graft acceptance with the least amount of side effects.
The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly-curated collaborative studies in highly informative cohorts in kidney transplants.
The Perivan shareholder communications team were delighted to work with N+1 Singer who were appointed Nominated Adviser and Book Runner to Verici Dx on the successful publication of the 135-page admission document.
Admission to Trading on AIM
On 3rd November 2020 admission and dealings commenced in the Ordinary Shares on AIM by way of an Issue of New Ordinary Shares in aggregate by way of Placing, Restricted Offer and Subscription at an Issue Price of 20 pence each.
Reasons for the admission
The Company believes that raising money in a public market context provides a signal of quality to prospective partners and customers raises the profile of the business and its products and provides a supportive platform on which to grow the business further through in-licensing of additional technologies or selective acquisition as appropriate.
The Directors also believe that the Fundraising and Admission will also provide an opportunity to align the interests of key stakeholders in the business. The net proceeds of the Fundraising, after the payment of Admission and Fundraising-related fees and expenses of approximately £0.99 million, in the first 21 months post Admission, will be used by the Company as follows:
- An estimated £2.41 million to undertake clinical utility and validation studies for the Clarava™ and Tuteva™ products, which are expected to begin in late 2020;
- An estimated £1.11 million on bioinformatics and health economic studies;
- An estimated £2.50 million on staff and related benefits;
- An estimated £1.88 million for general corporate overheads, including marketing and business development and for general working capital purposes; and
- An estimated £1.44 million on licence and royalties and capital expenditure (including to build additional testing capacity) and resourcing potential strategic partnerships.
With the balance of approximately £4.17 million being available as a contingency against delays in revenue or increased costs and providing additional working capital beyond the 21-month period following Admission.
Perivan specialise in the production and publication of financial documents relating to shareholder and investor communications for quoted companies, private companies and open and closed ended funds.